PCR117 Meaningful Change Thresholds in Patient-Reported Outcome Scores for Patients with Colorectal Cancer – A Systematic Literature Review

Abstract

In the ongoing phase 3 CodeBreaK 300 trial, the efficacy and safety of sotorasib and panitumumab is compared with investigator’s choice (trifluridine/tipiracil, or regorafenib) in previously treated metastatic CRC (mCRC) patients with KRAS p.G12C mutation. Secondary and exploratory endpoints include the evaluation of health-related quality of life (HRQoL). To assess clinically important changes in HRQoL, reference values for minimally important differences (MID) are needed. This study reviewed the literature to identify MID thresholds established in CRC.